Lapses on record-keeping Affects numerous, widely-used medications Preventive action to protect quality of drugs WASHINGTON: U.S. health officials have blocked dozens of drugs made by Ranbaxy Laboratories after the generic drugmaker failed to fix numerous record-keeping and other operational problems, although the medications themselves are considered safe. The U.S. Food and Drug Administration said on Tuesday it would block more than 30 generic drugs from entering the U.S. following ongoing procedural violations in manufacturing at Ranbaxy